Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
A recent study by investigators from Hong Kong showed that poor sleep quality and longer sleep onset latency is associated with an increased risk of peptic ulcer disease (PUD) recurrence. Depression is also shown to be associated with subsequent incidence of PUD.
Vitamin D supplementation does not appear to improve relapse-free survival in patients with digestive tract cancers who have undergone surgery, according to a recent study.
Treatment with gabapentin significantly improves symptoms of functional dyspepsia in a retrospective, open-label cohort of patients, reports an open-label study.
Gastric emptying occurs faster with elemental liquid diets than standard semisolid diets in bedridden percutaneous endoscopic gastronomy (PEG)-fed patients, results from two studies have shown. In addition, aspiration pneumonia may be prevented or reduced with elemental liquid diet tube feedings.
Cannabis use disorder appears to exert a beneficial effect on the risk of disorders of gut–brain interaction and inflammatory bowel disease in patients with schizophrenia but not in population controls, a study has found. This finding raises the possibility of new targets for treatment and prevention of digestive organ disorders in schizophrenia.
An individualized, food-based diet may be a potential treatment approach for patients with active Crohn’s disease, successfully replicating microbiome changes elicited by exclusive enteral nutrition and reducing gut inflammation, a recent study has shown.
Faecal microbiota transplantation combined with vancomycin is superior to vancomycin alone or fidaxomicin alone in patients with recurrent Clostridium difficile (rCDI) infections, a recent study has found.
Special Reports
There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.1 Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
Conference Reports
Joint pain is the most common extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD), according to a presentation during AIBD 2018.
The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.
The incidence of Clostridium difficile (C. difficile) infection among patients with ulcerative colitis (UC) who are receiving treatment with tofacitinib is low and particularly so when compared with C. difficile infection incidence in patients receiving other UC therapies, according to a poster presented at AIBD 2018.
Patients with paediatric-onset inflammatory bowel disease (pIBD) have a higher incidence of severe IBD than those with adult-onset IBD (aIBD), according to a study presented at AIBD 2018.
Older patients receiving treatment for ulcerative colitis (UC) were more likely to experience adverse events (AEs) compared with their younger counterparts, according to a study presented at AIBD 2018.
Patients with obesity have an elevated risk of intra- and postoperative complications following surgical treatment for inflammatory bowel disease (IBD), according to a presentation at the recent Advances in Inflammatory Bowel Disease meeting (AIBD 2018).
The α4β7 integrin antibody vedolizumab continues to show efficacy and safety in patients with inflammatory bowel disease (IBD) in an era beyond tumour necrosis factor (TNF) inhibitors, according to a presentation at the annual Advances in Inflammatory Bowel Diseases (AIBD) 2018 meeting.
.jpg)
